Journal
IMMUNOTHERAPY
Volume 3, Issue 4, Pages 507-516Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/IMT.11.18
Keywords
ACT; adoptive therapy; cancer immunotherapy; dendritic cell vaccine; T cell
Categories
Funding
- Cancer Vaccine Institute (London, UK)
- Celgene Corporation
Ask authors/readers for more resources
Therapies based on the use of autologous immune cells are among the best candidates for cancer immunotherapy. Dendritic cell vaccines have demonstrated very encouraging responses for some solid tumors, while in melanoma autologous T-cell therapies have exceeded 70% objective response rates in selected Phase I trials. However, it is clear that a number of barriers exist to the effective, practical application of these therapies. The aim of this article is to consider modifications to such strategies over the last 3 years and the resultant clinical research in autologous dendritic cell vaccines, T-cell therapy and gamma delta T-cell therapy for cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available